UBS has initiated coverage on Corcept Therapeutics Inc (CORT) with a Neutral rating, marking the firm's first assessment of the company's investment potential. This update provides insight into UBS's evaluation based on its research into Corcept's business, industry dynamics, and growth prospects.
Corcept, headquartered in Redwood City, California, is a commercial-stage pharmaceutical company focused on developing medications that modulate cortisol effects to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company markets Korlym (mifepristone) for treating Cushing's syndrome and has a robust portfolio of selective cortisol modulators, consisting of approximately 1,000 compounds.
As of December 15, 2025, Corcept's stock is priced at $81.13, with a market cap of $8.7 billion and a P/E ratio of 81.66. Analysts expect upcoming earnings on July 29, 2026, to report an EPS of $0.09 and revenue of $252.7 million.
Analyst ratings serve as professional opinions based on financial models and research, but they reflect assumptions that may not always materialize. Investors should consider a range of factors, including company fundamentals and industry trends, when making decisions. Analyst views should complement other inputs rather than serve as the sole basis for investment choices. It's also important to note that ratings can evolve as new information becomes available, leading to diverse opinions among analysts on the same company.